Transforming the delivery of life-changing, AI-enabled medical technology

Renalytix’s use of ground-breaking AI to assess patient biomarker data creates a unique opportunity to identify and save those most likely to progress to CKD. This is potentially life-changing for millions of people and a massive cost-saver for healthcare providers. In the U.S. alone, treatment of CKD accounts for 20% of the Medicare budget or $120 billion per year. 

Renalytix faced serious challenges. Trying to integrate their software with the patient systems for each new hospital or healthcare provider was going to take years. Getting clean, validated data into the system was difficult and often relied on manual input from paper-based sources. Also, the initial software builds were monolithic, difficult to change, and each amendment was further slowed by the need to comply with FDA quality controls on ‘medical device’ software.  

Renalytix selected us as their partner for accomplishing the company’s life-changing mission.

We quickly came up with an informed approach to create a smart and scalable platform, build capability and accelerate the new service into Renalytix’s target market. This was driven by some key focus points established during our discovery process:

• Re-categorising Renalytix’s existing software so only the core data/AI diagnostic modules were designated as a ‘medical device’ under FDA rules. This reduces the time needed to make changes to much of the software.

• Creating a cloud-based ‘portal’ to make the Renalytix application available to physicians in a clinical setting without the need to pre-integrate with existing clinical systems. This accelerates the time to market and brings a ‘try before you buy’ offering to their business model.